Early safety check: how do failing organs handle new drugs?
NCT ID NCT06911320
Summary
This early-stage study aims to understand how a single dose of a new antiviral drug combination is processed by the body in people with severe liver or kidney impairment. It will compare the drug's levels and safety in these participants to a matched group of healthy volunteers. The goal is to gather essential safety data to guide future use of the drug in patients with these conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atea Study Site
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Atea Study Site
RECRUITINGTampa, Florida, 33603, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.